ALBUQUERQUE, New Mexico, Feb. 14, 2000 (PRIMEZONE) -- Cell Robotics International Inc. (OTCBB:CRII) shares have been recommended in an analyst report just released by WallStreet Research as an excellent buy opportunity for aggressive long-term investors.
WallStreet Research is a prominent research boutique led by Alan Stone, managing director of Alan Stone & Co. LLC. Stone was formerly an analyst and assistant portfolio manager at Merrill Lynch Asset Management and securities analyst at Prudential Insurance Co.'s Capital Markets Group.
WallStreet Research specializes in the microcap and smallcap investment arena, looking for emerging growth companies with strong management, unique or proprietary technology, significant market potential, financial strength and outstanding long-term earnings growth possibilities.
The report on Cell Robotics International Inc. is available, together with additional information about WallStreet Research, at www.WallSt-Research.com.
In summary of the report, Cell Robotics International is a scientific research and medical products company committed to enhancing the quality of life through technology. Cell Robotics develops, manufactures and markets a series of laser-based medical devices with applications in the blood sample collection, cellular manipulation and in vitro fertilization markets.
Among its products, the company offers the Lasette(r), an award-winning laser-based blood collection device, which is the only FDA-cleared alternative to the needle or steel blade lancet for drawing capillary blood.
Recently, Cell Robotics has launched the Personal Lasette, a compact version of this product into the enormous diabetic home testing market. Several large insurance companies have already authorized reimbursement for the Personal Lasette for patients on a case-by-case basis.
Trading under the symbol CRII, the company is well poised to move toward profitability by capitalizing on its research and development efforts, proprietary technology, market positioning and effective distribution arrangements and appears undervalued.
Additional information on all Cell Robotics products is available on the company's Web site at http://www.cellrobotics.com, by e-mail at crii@cellrobotics.com, or by telephone at 719/590-1793 or 505/343-1131.
As a cautionary note to investors, certain matters discussed in this news release may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such matters involve risks and uncertainties that may cause actual results to differ materially, including the following: changes in economic conditions, general competitive factors, the company's ability to execute its service and product sales plans and the risks described from time to time in the company's Securities and Exchange Commission filings.